These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14678863)

  • 1. Free fatty acids and type 2 diabetes mellitus.
    Wyne KL
    Am J Med; 2003 Dec; 115 Suppl 8A():29S-36S. PubMed ID: 14678863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance, diabetes, and the adipocyte.
    Stolar MW
    Am J Health Syst Pharm; 2002 Dec; 59 Suppl 9():S3-8. PubMed ID: 12489380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.
    Carpentier A; Mittelman SD; Bergman RN; Giacca A; Lewis GF
    Diabetes; 2000 Mar; 49(3):399-408. PubMed ID: 10868961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between free fatty acids and glucose metabolism.
    Boden G
    Curr Opin Clin Nutr Metab Care; 2002 Sep; 5(5):545-9. PubMed ID: 12172479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes.
    Boden G
    Exp Clin Endocrinol Diabetes; 2003 May; 111(3):121-4. PubMed ID: 12784183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
    Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
    J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M; Vantyghem MC; Schoonjans K; Pattou F
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance in type 2 diabetes: role of fatty acids.
    Arner P
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S5-9. PubMed ID: 11921432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones.
    Del Prato S; Marchetti P
    Diabetes Technol Ther; 2004 Oct; 6(5):719-31. PubMed ID: 15628822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease.
    Uwaifo GI; Ratner RE
    Am J Med; 2003 Dec; 115 Suppl 8A():12S-19S. PubMed ID: 14678860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
    Boden G; Chen X
    Diabetes; 1999 Mar; 48(3):577-83. PubMed ID: 10078559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.
    Julius U
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):246-50. PubMed ID: 12951628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel actions of thiazolidinediones on vascular function and exercise capacity.
    Reusch JE; Regensteiner JG; Watson PA
    Am J Med; 2003 Dec; 115 Suppl 8A():69S-74S. PubMed ID: 14678869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA).
    Arends NJ; Boonstra VH; Duivenvoorden HJ; Hofman PL; Cutfield WS; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):44-50. PubMed ID: 15638869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease.
    Henderson GC
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free fatty acids normalize a rosiglitazone-induced visfatin release.
    Haider DG; Mittermayer F; Schaller G; Artwohl M; Baumgartner-Parzer SM; Prager G; Roden M; Wolzt M
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E885-90. PubMed ID: 16735449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance and the effects of thiazolidinediones on cardiac metabolism.
    Young LH
    Am J Med; 2003 Dec; 115 Suppl 8A():75S-80S. PubMed ID: 14678870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.